HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Investors Bet On UK/Singapore Biotech To Disrupt Personalized Skin Care

Executive Summary

Sequential Skin, whose genetic and microbiome home test kit sells for $149, raised $1.65m in a seed round announced on 11 October. The UK/Singapore biotech will use the funds to roll out the kit in the US while extending its B2B offering to skin care, hair care and health care companies for clinical trial and product validation purposes.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel